9 June 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice on four medicines.

Cladribine (Mavenclad) was accepted for the treatment of relapsing-remitting multiple sclerosis in adults who have signs of active disease either through clinical signs or evidence of inflammation on scans.

Read SMC press release